Results for this period
Interim period (second quarter)1 April 2026–30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Thousands of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from antibody research support was ¥7.158 million, up 10.0% year on year, while revenue from antibody and reagent sales was ¥45.471 million, down 16.5%. Selling, general and administrative expenses were ¥458.446 million, up 0.3% year on year, and an impairment loss of ¥4.024 million on fixed assets was recorded as an extraordinary loss.
None (the note on the going concern assumption states, “There are no applicable matters.”)
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | 52 Millions of yen (YoY -13.7%) |
| Operating profit | -411 Millions of yen |
| Ordinary income | -394 Millions of yen |
| Profit attributable to owners of the parent | -399 Millions of yen |
| Net income per share | -¥22.47 |
| Equity ratio | End of the current fiscal period 62.7 / End of previous period 70.1 |
| Total assets | 1,506 Millions of yen |
| Net assets | 1,029 Millions of yen |
| Cash flows from operating activities | -292,375 Thousands of yen |
| Cash flows from investing activities | -1,141 Thousands of yen |
| Cash flows from financing activities | 202,406 Thousands of yen |
| Cash and cash equivalents at end of period | 1,420,154 Thousands of yen |
| Annual Dividend Forecast | 0 Yen → 0 Yen（0.0%） |
| Depreciation and amortization | 71 Thousands of yen |
| Impairment loss | 4,024 Thousands of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses 4,024 Thousands of yen |
| Disclosure regarding the going concern assumption | None (the note on the going concern assumption states, “There are no applicable matters.”) |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | Held (for institutional investors and analysts) |
| Issued Shares at Period-End | 18,429,500 shares |
| Treasury Shares at Period-End | 90 shares |
| Factors Behind Changes in Business Performance | Revenue from antibody research support was ¥7.158 million, up 10.0% year on year, while revenue from antibody and reagent sales was ¥45.471 million, down 16.5%. Selling, general and administrative expenses were ¥458.446 million, up 0.3% year on year, and an impairment loss of ¥4.024 million on fixed assets was recorded as an extraordinary loss. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from antibody and reagent sales fell 16.5% year on year, while selling, general and administrative expenses increased 0.3%. In addition, an impairment loss of ¥4.024 million on fixed assets was recorded as an extraordinary loss.